Does eating more fat automatically mean that more harmful fatty acids will circulate in the blood? A new randomized trial suggests the answer may be more complicated. Researchers studying a low-carb diet for type 2 diabetes found that six months of carbohydrate restriction changed circulating fatty acids in potentially favorable …
Read More »Beyond hs-CRP: Could suPAR Reveal Hidden Heart Risk in Type 2 Diabetes?
People with type 2 diabetes can face substantial cardiovascular risk even when clinicians address familiar risk factors such as LDL cholesterol, blood pressure, smoking, and blood glucose. Could another blood marker help reveal some of the risk that remains? Emerging research on the suPAR biomarker in diabetes suggests it may …
Read More »Two Shots a Year for Hypertension? How RNA Silencing Could Transform Cardiometabolic Care
Poor medication persistence remains one of the hardest barriers to long-term blood pressure control. For people with diabetes, the stakes are especially high because hypertension adds to cardiovascular and kidney risk. Now, research into RNAi for hypertension in people with diabetes is raising an intriguing possibility: could an injection given …
Read More »Your Eye Exam May Be Predicting More Than Vision Loss: AI Is Finding Hidden Diabetes Risks
For people with diabetes, a retinal photograph has traditionally answered one major question: Is diabetic retinopathy developing? However, artificial intelligence is beginning to uncover much more. Emerging retinal AI models for systemic risk assessment can detect patterns associated with cardiovascular disease, kidney disease, blood pressure, and metabolic health. As a …
Read More »LDL Is Under Control—So Why Is Heart Risk Still High? Solving the Lipoprotein(a) Puzzle
For many people with diabetes, lowering LDL cholesterol is a major part of preventing heart attack and stroke. Yet an important clinical puzzle remains. Why do some patients experience cardiovascular events even after LDL reaches recommended targets? Growing evidence points toward lipoprotein(a), or Lp(a), as one possible piece of that …
Read More »The Return of Aldose Reductase Inhibitors: Could an Old Idea Finally Pay Off?
Diabetes care has advanced dramatically over the past decade. While therapies such as GLP-1 receptor agonists and SGLT2 inhibitors have transformed glucose management and cardiovascular outcomes, many patients continue to develop long-term complications. Could an older therapeutic target finally provide the missing piece? Interest in aldose reductase inhibitors for diabetes …
Read More »Your LDL Is Normal—So Why Is Your Heart Risk Still High?
For years, lowering LDL cholesterol has been the cornerstone of preventing heart disease in people with diabetes. Statins and other cholesterol-lowering therapies have dramatically reduced cardiovascular events. Yet many patients continue to experience heart attacks, strokes, or other cardiovascular complications despite reaching recommended LDL cholesterol goals. Why does this happen? …
Read More »Could This Heart Scan Detect Diabetes Damage Before Symptoms Appear?
Heart disease remains the leading cause of illness and death among people with diabetes. However, one of the most concerning complications, diabetic cardiomyopathy, often develops quietly for years before symptoms emerge. During this silent phase, routine echocardiograms frequently show a normal ejection fraction, creating a false sense of reassurance. Fortunately, …
Read More »Why Cardiologists Are Looking Beyond Traditional SGLT2 Therapy
The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By …
Read More »The Blood Vessel Damage Doctors Can’t See—Until It’s Too Late
Most people think diabetes-related blood vessel damage begins only after years of high blood sugar. However, scientists are uncovering evidence that injury may start much earlier, in a structure so thin it cannot be seen during a routine medical exam. This microscopic layer, known as the endothelial glycocalyx, acts as …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.